Apyx Medical Corporation reported second quarter 2026 financial results for the period ended June 30, 2026. Total revenue increased 22% to $13.9 million from $11.4 million in the prior year, driven by a 28% growth in the Surgical Aesthetics segment to $12.4 million. The company initiated limited commercial shipments of its reusable power liposuction handpiece for the AYON platform in June 2026 following expanded FDA clearance. Net loss attributable to stockholders narrowed to $3.2 million, or $0.07 per share, compared to a $3.8 million loss in the previous year. Adjusted EBITDA improved significantly, with a loss of $0.7 million versus $2.0 million previously. The company reaffirmed its full-year 2026 revenue guidance of $59.0 million to $60.0 million and reported cash and cash equivalents of $27.6 million as of June 30, 2026. Apyx Medical Corporation operates in the surgical aesthetics industry, developing and marketing medical devices such as Renuvion and the AYON Body Contouring System.

On June 11, 2026, Apyx Medical Corporation appointed Stavros Vizirgianakis, the current Chairman of the Board, as Executive Chairman. In connection with this appointment, the Board granted Mr. Vizirgianakis 450,000 restricted stock units (RSUs). 150,000 RSUs vested immediately on June 11, 2026, while the remaining 300,000 RSUs will vest ratably over 12-month periods starting on the first and second anniversaries of the grant date, respectively. Mr. Vizirgianakis will provide strategic leadership and governance oversight but will not serve as an officer or employee. The company operates in the medical device industry, developing and commercializing medical technologies.